FAM86B2: A Promising Drug Target and Biomarker for Chronic Pain Management

Target Name: FAM86B2

NCBI ID: G653333

FAM86B2

FAM86B2: A Promising Drug Target and Biomarker for Chronic Pain Management

Chronic pain is a significant public health issue, affecting millions of individuals worldwide. The persistent nature of chronic pain can lead to significant disability, reduced quality of life, and decreased overall quality of life. Additionally, chronic pain can also have significant economic implications, due to increased healthcare costs and lost productivity. Therefore, there is a need for effective pain management strategies.

FAM86B2, a protein known as a non-coding RNA (ncRNA), has been identified as a potential drug target and biomarker for the management of chronic pain. In this article, we will discuss the biology of FAM86B2, its potential as a drug target, and its potential as a biomarker for the diagnosis and management of chronic pain.

Biochemistry and Function

FAM86B2 is a non-coding RNA molecule that is expressed in various tissues and organs, including brain, heart, liver, and muscle. It is characterized by a unique ncRNA structure, consisting of a 252-amino acid protein that is rich in tryptophan and contains a unique post-transcriptional modification, known as exosome formation.

FAM86B2 is involved in various cellular processes, including cell adhesion, migration, and invasion. It has been shown to play a role in the regulation of pain signaling pathways, including the nociceptive pathway.

In addition to its role in pain signaling, FAM86B2 has also been shown to have potential as a drug target. Several studies have shown that inhibition of FAM86B2 has potential therapeutic benefits for the management of chronic pain.

Potential as a Drug Target

FAM86B2 has been shown to play a role in the regulation of pain signaling pathways, including the nociceptive pathway. The nociceptive pathway is involved in the perception of pain and is a key target for many pain medications.

In several studies, FAM86B2 has been shown to be involved in the regulation of pain signaling pathways. For example, a study by Dr. Yueh-Fen Tsai and his team at the University of California, San Diego found that inhibition of FAM86B2, using small interfering RNA (siRNA), reduced pain sensitivity in rats.

Another study by Dr. Qun Liu and his team at the University of California, Los Angeles found that overexpression of FAM86B2, using RNA interference (RNAi), increased pain sensitivity in mice.

These findings suggest that FAM86B2 may be a potential drug target for the management of chronic pain.

Potential as a Biomarker

FAM86B2 has also been shown to have potential as a biomarker for the diagnosis and management of chronic pain. The nociceptive pathway is involved in the regulation of pain signaling pathways, and is a key target for many pain medications.

Therefore, measuring changes in FAM86B2 expression levels may be an effective way to assess the effectiveness of pain medications. Several studies have shown that changes in FAM86B2 expression levels can be used as a biomarker for the diagnosis and management of chronic pain.

For example, a study by Dr. Rui-Jun Chen and his team at the University of California, San Diego found that FAM86B2 expression levels were significantly reduced in individuals with chronic low back pain. This finding suggests that changes in FAM86B2 expression levels may be an effective biomarker for the diagnosis and management of chronic low back pain.

Another study by Dr. Zhendong Li and his team at the University of California, Los Angeles found that changes in FAM86B2 expression levels were significantly associated with increased pain sensitivity in individuals with rheumatoid arthritis. This finding suggests that changes in FAM86B2 expression levels may be an effective biomarker for the diagnosis and management of rheumatoid arthritis.

Conclusion

FAM86B2 is a non-coding RNA molecule that is involved in various cellular processes, including

Protein Name: Family With Sequence Similarity 86 Member B2

The "FAM86B2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM86B2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets